Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1960027 | 0.80 | HMGCR (0.50) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL1005147 | 0.80 | TSHR (0.42) | TSHRALDH1A1TP53HMGCRCHRM1 | |
| SCHEMBL13880069 | 0.80 | ALDH1A1 (0.33) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL388297 | 0.79 | — | — | |
| SCHEMBL377850 | 0.78 | KMT2A (0.31) | HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL25246442 | 0.77 | TSHR (0.41) | TSHRALDH1A1TP53HMGCRCHRM1 | |
| SCHEMBL665258 | 0.75 | TSHR (0.45) | TSHRALDH1A1TP53HMGCRCHRM1 | |
| SCHEMBL212208 | 0.75 | — | — | |
| SCHEMBL12339113 | 0.75 | TSHR (0.32) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL3847858 | 0.74 | TSHR (0.39) | TSHRALDH1A1TP53HMGCRCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023698-A1 | METHODS OF MANUFACTURING BIOACTIVE 3-ESTERS OF BETULINIC ALDEHYDE AND BETULINIC ACID | KRASUTSKY PAVEL A | 2009-01-22 | — | — | US | claimed |
| EP-1869063-A2 | METHODS OF MANUFACTURING BIOACTIVE 3-ESTERS OF BETULINIC ALDEHYDE AND BETULINIC ACID | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006105356-A2 | METHODS OF MANUFACTURING BIOACTIVE 3-ESTERS OF BETULINIC ALDEHYDE AND BETULINIC ACID | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2006-10-05 | — | — | WO | claimed |
| CN-117122721-A | Sponge | 贵州省农作物品种资源研究所 | 2023-11-28 | — | — | CN | disclosed |
| US-20110015198-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM | BANYU PHARMACEUTICAL CO., INC. | 2011-01-20 | — | — | US | disclosed |
| EP-2272841-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING ANTAGONISTIC ACTIVITY ON MELANIN-CONCENTRATING HORMONE RECEPTOR | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090023698-A1 | METHODS OF MANUFACTURING BIOACTIVE 3-ESTERS OF BETULINIC ALDEHYDE AND BETULINIC ACID | KRASUTSKY PAVEL A | 2009-01-22 | — | — | US | disclosed |
| US-20090023698-A1 | METHODS OF MANUFACTURING BIOACTIVE 3-ESTERS OF BETULINIC ALDEHYDE AND BETULINIC ACID | KRASUTSKY PAVEL A | 2009-01-22 | — | — | US | disclosed |
| EP-1869063-A2 | METHODS OF MANUFACTURING BIOACTIVE 3-ESTERS OF BETULINIC ALDEHYDE AND BETULINIC ACID | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1869063-A2 | METHODS OF MANUFACTURING BIOACTIVE 3-ESTERS OF BETULINIC ALDEHYDE AND BETULINIC ACID | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006105356-A3 | METHODS OF MANUFACTURING BIOACTIVE 3-ESTERS OF BETULINIC ALDEHYDE AND BETULINIC ACID | UNIV MINNESOTA (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-1051655-B1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | ISTA PHARMACEUTICALS INC (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1051655-A4 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | ISTA PHARMACEUTICALS INC (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20010016731-A1 | Methods and apparatus for accelerated orthokeratology | DEVORE DALE (US) | 2001-08-23 | — | — | US | disclosed |
| CN-1295677-A | Method and apparatus for accelerated orthokeratology | EASTA PHARMACEUTICALS INC (US) | 2001-05-16 | — | — | CN | disclosed |
| US-6161544-A | Methods for accelerated orthokeratology | KERATOFORM, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| EP-1051655-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | Ista Pharmaceuticals, Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999039238-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | KERATOFORM, INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| US-4219676-A | FREE RADICAL POLYMERIZATION CATALYSTS | PENNWALT CORPORATION (US) | 1980-08-26 | — | — | US | disclosed |
| US-4079074-A | FREE RADICAL CATALYSTS, CURING AGENTS FOR UNSATURATED POLYESTERS | PENNWALT CORPORATION (US) | 1978-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023698-A1 | METHODS OF MANUFACTURING BIOACTIVE 3-ESTERS OF BETULINIC ALDEHYDE AND BETULINIC ACID | BET1, ALDH7A1, CA7 | TSHR 4033/4885ALDH1A1 8/4885TP53 2976/4885 |
| US-20110015198-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM | MC1R, MCHR2, MCHR1 | TSHR 23/4885ALDH1A1 2052/4885TP53 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.